Recent News

• 08.06.2026 - Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
• 07.23.2026 - Cytokinetics to Announce Second Quarter Results on August 6, 2026
• 07.17.2026 - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 07.07.2026 - Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026
• 06.17.2026 - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.08.2026 - Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
• 06.01.2026 - Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
• 06.01.2026 - Cytokinetics bringt MYQORZO® (aficamten) in der Europäischen Union auf den Markt; der erste kommerzielle Vertrieb erfolgt in Deutschland
• 05.27.2026 - Cytokinetics to Participate in June Investor Conferences
• 05.20.2026 - Cytokinetics to Hold Annual Meeting of Stockholders

Recent Filings

• 08.06.2026 - EX-99.1 EX-99.1
• 08.06.2026 - 8-K Current report
• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.30.2026 - 144 Report of proposed sale of securities
• 07.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.16.2026 - 4 Statement of changes in beneficial ownership of securities